Cytomegalovirus (CMV) Clinical Trial
Official title:
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05319353 -
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection
|
Phase 3 | |
Completed |
NCT05571137 -
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
|
||
Not yet recruiting |
NCT06243731 -
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
|
||
Not yet recruiting |
NCT06439342 -
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
|
Phase 3 | |
Completed |
NCT05576805 -
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
|
||
Not yet recruiting |
NCT06213974 -
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
|
||
Completed |
NCT02775240 -
Study of SHP620 (Maribavir) in Healthy Adults
|
Phase 1 | |
Completed |
NCT01611974 -
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
|
Phase 2 | |
Completed |
NCT05137717 -
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
|
Phase 3 | |
Completed |
NCT02927067 -
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
|
Phase 3 |